Having shown that 5-FU may require MEK5/ERK5 signaling inhibition to effectively trigger its anticancer effects, we next investigated whether MEK5/ERK5 differential activation could determine colon cancer cell sensitivity to this chemotherapeutic drug. The gene discussed is MAPK7; the disease is malignant colon neoplasm.